Ego Silicon New Zealand - English - Medsafe (Medicines Safety Authority)

ego silicon

douglas pharmaceuticals limited - dimeticone 15%{relative} - topical cream - 15 % - active: dimeticone 15%{relative} excipient: cetyl alcohol glycerol liquid paraffin methyl hydroxybenzoate propyl hydroxybenzoate purified water self-emulsifying glyceryl monostearate

Egozite Protective Baby Lotion New Zealand - English - Medsafe (Medicines Safety Authority)

egozite protective baby lotion

douglas pharmaceuticals limited - dimeticone 15% - lotion - 15 % - active: dimeticone 15% excipient: carbomer cetomacrogol 1000 cetyl alcohol glycerol glyceryl monostearate light liquid paraffin methyl hydroxybenzoate propyl hydroxybenzoate purified water trolamine

Ego Baby Cream New Zealand - English - Medsafe (Medicines Safety Authority)

ego baby cream

douglas pharmaceuticals limited - dimeticone 15%{relative} (350); light liquid paraffin 10%{relative}; zinc oxide 15%{relative} - topical cream - active: dimeticone 15%{relative} (350) light liquid paraffin 10%{relative} zinc oxide 15%{relative} excipient: cetostearyl alcohol dexpanthenol glycerol ceteareth-25 methyl hydroxybenzoate propyl hydroxybenzoate purified water xanthan gum

Sprilon 12.5 % Zinc Oxide and 1.04 % Dimeticone Cutaneous Spray, Suspension Ireland - English - HPRA (Health Products Regulatory Authority)

sprilon 12.5 % zinc oxide and 1.04 % dimeticone cutaneous spray, suspension

ayrton saunders (ireland) limited - dimeticone 350; zinc oxide - cutaneous spray, suspension - 12.5%w/w + 1.04 percent weight/weight - zinc products

Dimeticone 10% cream United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dimeticone 10% cream

a a h pharmaceuticals ltd - dimeticone 350 - cutaneous cream - 100mg/1gram

EGO SILICON CREAM dimeticone 350 150mg/g cream jar Australia - English - Department of Health (Therapeutic Goods Administration)

ego silicon cream dimeticone 350 150mg/g cream jar

ego pharmaceuticals pty ltd - dimeticone 350, quantity: 150 mg/g - cream - excipient ingredients: self-emulsifying glyceryl monostearate; purified water; cetyl alcohol; light liquid paraffin; propyl hydroxybenzoate; glycerol; methyl hydroxybenzoate - helps protect the skin from water, chemicals and other external irritants. helps prevent dermatitis and dry skin. helps relieve the symptoms of eczema. helps prevent blisters and chafing during sport. helps to prevent bed sores. helps protecting skin and surrounding colostomy site. helps to protect traumatised skin from further irritation. helps prevent dribble and napkin rash.

Sprilon 12.5 % Zinc Oxide and 1.04 % Dimeticone Cutaneous Spray, Suspension Ireland - English - HPRA (Health Products Regulatory Authority)

sprilon 12.5 % zinc oxide and 1.04 % dimeticone cutaneous spray, suspension

ayrton saunders ltd - zinc oxide; dimeticone 350 - cutaneous spray, solution - 12.5%w/w + 1.04 percent weight/weight - zinc products

Aero-OM, dimethicone Malta - English - Medicines Authority

aero-om, dimethicone

om pharma s.a. r. da industria, 2, 2610-088 amadora, lisboa, portugal - dimeticone - oral drops, solution - dimeticone 100 mg/ml - drugs for acid related disorders

Aero-OM, dimethicone Malta - English - Medicines Authority

aero-om, dimethicone

om pharma s.a. r. da industria, 2, 2610-088 amadora, lisboa, portugal - dimeticone - tablet - dimeticone 40 mg - drugs for acid related disorders

EXELON PATCH 15 rivastigmine 13.3mg/24 hours transdermal drug delivery system sachet Australia - English - Department of Health (Therapeutic Goods Administration)

exelon patch 15 rivastigmine 13.3mg/24 hours transdermal drug delivery system sachet

novartis pharmaceuticals australia pty ltd - rivastigmine, quantity: 27 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; dl-alpha-tocopherol; dimeticone 12500; ethyl acetate; methylated trimethylated silica; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - exelon / prometax is indicated for the treatment of patients with mild, moderate and severe dementia of the alzheimer's type.